DOTA-Functionalized Polylysine: A High Number of DOTA Chelates Positively Influences the Biodistribution of Enzymatic Conjugated Anti-Tumor Antibody chCE7agl

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Grünberg, Jürgen ^a   Jeger, Simone ^a   Sarko, Dikran ^b   Dennler, Patrick ^a   Zimmermann, Kurt ^a   Mier, Walter ^b   Schibli, Roger ^a  

^a ETH Zurich   (Switzerland)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; LUTETIUM MONOCLONAL ANTIBODY CHCE7AGL(TETRAXETAN DECALYSINE)2 LU 177; LUTETIUM MONOCLONAL ANTIBODY CHCE7AGL[(TETRAXETAN)3 DECALYSINE]2 LU 177; LUTETIUM MONOCLONAL ANTIBODY CHCE7AGL[(TETRAXETAN)5 DECALYSINE]2 LU 177; MICROBIAL TRANSGLUTAMINASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CHCE7AGL[(TETRAXETAN)N DECALYSINE]2; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; OVARY CANCER; PLASMA CLEARANCE; RADIOACTIVITY; STOICHIOMETRY; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHELATING AGENTS; FEMALE; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAINS; MICE; OVARIAN NEOPLASMS; POLYLYSINE; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; TRANSGLUTAMINASES; TRANSPLANTATION, HETEROLOGOUS;

EID: 84875681906     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060350     Document Type: Article

References (33)

1. Carter PJ, Senter PD, (2008) Antibody-drug conjugates for cancer therapy. Cancer Journal 14: 154-169.
2. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, et al. (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nature Biotechnology 21: 778-784.
3. Junutula JR, Bhakta S, Raab H, Ervin KE, Eigenbrot C, et al. (2008) Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs. Journal of Immunological Methods 332: 41-52.
4. Jeger S, Zimmermann K, Blanc A, Grünberg J, Honer M, et al. (2010) Site-Specific and Stoichiometric Modification of Antibodies by Bacterial Transglutaminase. Angewandte Chemie International Edition 49: 9995-9997.
5. Rodwell JD, McKearn TJ, (1985) Linker Technology- Antibody-Mediated Delivery Systems. Bio-Technology 3: 889-894.
6. Meares CF, Goodwin DA, (1984) Linking Radiometals to Proteins with Bifunctional Chelating-Agents. Journal of Protein Chemistry 3: 215-228.
7. Ducry L, Stump B, (2009) Antibody Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies. Bioconjugate Chemistry 21: 5-13.
8. Garnett MC, (2001) Targeted drug conjugates: principles and progress. Advanced Drug Delivery Reviews 53: 171-216.
9. Chapman AP, Antoniw P, Spitali M, West S, Stephens S, et al. (1999) Therapeutic antibody fragments with prolonged in vivo half-lives. Nature Biotechnology 17: 780-783.
10. Firestone RA, Willner D, Hofstead SJ, King HD, Kaneko T, et al. (1996) Synthesis and antitumor activity of the immunoconjugate BR96-Dox. Journal of Controlled Release 39: 251-259.
11. Allen TM, (2002) Ligand-targeted therapeutics in anticancer therapy. Nature Reviews Cancer 2: 750-763.
12. Kukis DL, DeNardo GL, DeNardo SJ, Mirick GR, Miers LA, et al. (1995) Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates. Cancer Research 55: 878-884.
13. vanGog FB, Visser GWM, Klok R, vanderSchors R, Snow GB, et al. (1996) Monoclonal antibodies labeled with rhenium-186 using the MAG3 chelate: Relationship between the number of chelated groups and biodistribution characteristics. Journal of Nuclear Medicine 37: 352-362.
14. Knogler K, Grünberg J, Novak-Hofer I, Zimmennann K, Schubiger PA, (2006) Evaluation of Lu-177-DOTA-labeled aglycosylated monoclonal anti-L1-CAM antibody chCE7: influence of the number of chelators on the in vitro and in vivo properties. Nuclear Medicine and Biology 33: 883-889.
15. Slinkin MA, Klibanov AL, Khaw BA, Torchilin VP, (1990) Succinylated polylysine as a possible link between an antibody molecule and deferoxamine. Bioconjugate Chemistry 1: 291-295.
16. Wängler C, Moldenhauer G, Eisenhut M, Haberkorn U, Mier W, (2008) Antibody-dendrimer conjugates: the number, not the size of the dendrimers, determines the immunoreactivity. Bioconjugate Chemistry 19: 813-820.
17. Ramli M, Smith SV, Lindoy LF, (2009) Investigation of Novel Bis- and Tris-tetraazamacrocycles for Use in the Copper-64 ((64)Cu) Radiolabeling of Antibodies with Potential To Increase the Therapeutic Index for Drug Targeting. Bioconjugate Chemistry 20: 868-876.
18. Lorand L, Graham RM, (2003) Transglutaminases: Crosslinking enzymes with pleiotropic functions. Nature Reviews Molecular Cell Biology 4: 140-156.
19. Mier W, Graham KAN, Wang Q, Kramer S, Hoffend J, et al. (2004) Synthesis of peptide conjugated chelator oligomers for endoradiotherapy and MRT imaging. Tetrahedron Letters 45: 5453-5455.
20. Fischer E, Grünberg J, Cohrs S, Hohn A, Waldner-Knogler K, et al. (2012) L1-CAM-targeted antibody therapy and (177)Lu-radioimmunotherapy of disseminated ovarian cancer. Int J Cancer 130: 2715-2721.
21. Knogler K, Grünberg J, Zimmermann K, Cohrs S, Honer M, et al. (2007) Copper-67 radioimmunotherapy and growth inhibition by anti-L1-cell adhesion molecule monoclonal antibodies in a therapy model of ovarian cancer metastasis. Clinical Cancer Research 13: 603-611.
22. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA, (1984) Determination of the Immunoreactive Fraction of Radiolabeled Monoclonal-Antibodies by Linear Extrapolation to Binding at Infinite Antigen Excess. Journal of Immunological Methods 72: 77-89.
23. Zimmermann K, Gianollini S, Schubiger PA, Novak-Hofer I, (1999) A triglycine linker improves tumor uptake and biodistributions of 67-Cu-labeled anti-neuroblastoma MAb chCE7 F(ab')2 fragments. Nuclear Medicine and Biology 26: 943-950.
24. Radaev S, Sun PD, (2001) Recognition of IgG by Fcgamma receptor. The role of Fc glycosylation and the binding of peptide inhibitors. Journal of Biological Chemistry 276: 16478-16483.
25. Mindt TL, Jungi V, Wyss S, Friedli A, Pla G, et al. (2008) Modification of different IgG1 antibodies via glutamine and lysine using bacterial and human tissue transglutaminase. Bioconjugate Chemistry 19: 271-278.
26. Fontana A, Spolaore B, Mero A, Veronese FM, (2008) Site-specific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase. Advanced Drug Delivery Reviews 60: 13-28.
27. Grootjans JJ, Groenen PJ, de Jong WW, (1995) Substrate requirements for transglutaminases. Influence of the amino acid residue preceding the amine donor lysine in a native protein. Journal of Biological Chemistry 270: 22855-22858.
28. Huber R, Deisenhofer J, Colman PM, Matsushima M, Palm W, (1976) Crystallographic structure studies of an IgG molecule and an Fc fragment. Nature 264: 415-420.
29. Spolaore B, Raboni S, Ramos Molina A, Satwekar A, Damiano N, et al. (2012) Local unfolding is required for the site-specific protein modification by transglutaminase. Biochemistry 51: 8679-8689.
30. Boswell CA, Mundo EE, Zhang C, Bumbaca D, Valle N, et al. (2011) Impact of Drug Conjugation on Pharmacokinetics and Tissue Distribution of Anti-STEAP1 Antibody-Drug Conjugates in Rats. Bioconjugate Chemistry 22: 1994-2004.
31. Slinkin MA, Curtet C, Faivre-Chauvet A, Sai-Maurel C, Gestin JF, et al. (1993) Biodistribution of anti-CEA F(ab')2 fragments conjugated with chelating polymers: Influence of conjugate electron charge on tumor uptake and blood clearance. Nuclear Medicine and Biology 20: 443-452.
32. Li G, Stewart R, Conlan B, Gilbert A, Roeth P, et al. (2002) Purification of human immunoglobulin G: a new approach to plasma fractionation. Vox sanguinis 83: 332-338.
33. Kukis DL, DeNardo GL, DeNardo SJ, Mirick GR, Miers LA, et al. (1995) Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates. Cancer Research 55: 878-884.